Background/Aims: It has been suggested that the serotonergic systems are associated with anger and aggressive behaviors. We investigated the association between several single nucleotide polymorphisms in the serotonergic genes and anger-related personality traits. Methods: A total of 228 healthy female Korean women participated in this study. All subjects were assessed with the State-Trait Anger Expression Inventory (STAXI) and were genotyped for 3 polymorphisms: serotonin transporter (5-HTT) gene-linked polymorphic region (5-HTTLPR), tryptophan hydroxylase 1 (TPH1) A218C, and TPH2 G-703T. Results: The Anger Expression-Out (AX-Out) subscale scores of the STAXI differed significantly between the genotypes for the TPH2 G-703T polymorphism (F = 4.825, p = 0.009). G/G homozygous subjects scored significantly higher on the AX-Out subscale than those with the G/T genotype. However, no significant differences were observed in the relationships between the STAXI subscale scores of subjects with other polymorphisms. Conclusions: This study suggests that the TPH2 G-703T polymorphism might contribute to anger-related traits, especially to the expression of anger.

Keywords:
Anger, Tryptophan hydroxylase 2, Polymorphism
This content is only available via PDF.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.